# Who does Cencora, Inc. pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/cencora · Facet: suppliers · Updated: 2026-09-24T04:08:55.115819+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Cencora, Inc.'s confirmed suppliers/cost counterparties include Amgen, Bristol-Myers Squibb Company, Biogen Inc. plus 6 undisclosed/aggregate relationships. Per the valuechain.wiki graph: 9 cost edges, backed by 12 dated sources, 10 of them primary filings (as of 2026-09-24).

### 암젠 (high)  → /amgen.md
- metric: Amount $21B · FY2025 · Amgen gross product sales to Cencora
- note: Cencora purchases Amgen medicines for distribution to healthcare providers and pharmacies. Amgen reported USD 20.986 billion of FY2025 gross product sales to Cencora.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-13) https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm: "Gross product sales $20,986"

### 레티나 컨설턴츠 오브 아메리카 (high)
- metric: Contract value $4B · 2025 acquisition · Cash purchase price paid for an 85% interest in RCA
- note: Cencora acquired an 85% interest in the retina practice management organization RCA in January 2025 for USD 4.042 billion in cash. The metric captures only the cash purchase price and excludes settlement of the pre-existing commercial receivable and contingent consideration.
- [mentions] Etoday (KO, news, published 2026-08-20) https://v.daum.net/v/6m6BudyOTb: "It has recently expanded into healthcare services by acquiring management services organizations."
- [confirms] SEC EDGAR (EN, filing, published 2025-11-25) https://www.sec.gov/Archives/edgar/data/1140859/000114085925000131/cor-20250930.htm: "acquired an 85% interest in Retina Consultants of America"
- [confirms] VMG Health (EN, analysis, published 2025-06-19) https://vmghealth.com/insights/blog/strategic-consolidation-in-oncology/: "Cencora also announced its acquisition of Retina Consultants of America"

### 브리스톨 마이어스 스퀴브 (high)  → /bristol-myers-squibb.md
- note: Cencora is BMS's second-largest U.S. pharmaceutical wholesale customer, with gross revenue to Cencora representing 29% of BMS's U.S. gross revenue in 2025.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-11) https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm: "Cencora, Inc. | 29% | 29% | 29%."

### 바이오젠 (high)  → /biogen.md
- note: Cencora, then named AmerisourceBergen, was a major U.S. wholesale distributor for Biogen and accounted for more than 10% of Biogen's total revenue and 33% of its gross product revenue in FY2014.
- [confirms] SEC EDGAR (EN, filing, published 2015-02-04) https://www.sec.gov/Archives/edgar/data/875045/000087504515000005/biib-20141231x10k.htm: "We recorded revenue from two wholesalers accounting for 33% and 27% of gross product revenues in 2014, respectively."

### 애브비 (high)  → /abbvie.md
- note: Cencora is a major U.S. wholesale customer purchasing AbbVie medicines. AbbVie said three wholesalers including Cencora represented substantially all of its FY2025 U.S. pharmaceutical sales, but did not disclose Cencora's individual amount.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-20) https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm: "accounted for substantially all of AbbVie's pharmaceutical product sales in the United States"

### 화이자 (high)  → /pfizer.md
- note: Cencora is Pfizer's second-largest U.S. wholesaler customer and accounted for a material share of FY2025 total revenue.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-26) https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/pfe-20251231.htm: "Cencora, Inc. 16%."

### 길리어드 사이언스 (high)  → /gilead-sciences.md
- note: Cencora and its specialty distributor affiliates are major U.S. wholesale customers of Gilead and represented 21% of Gilead's total gross product sales in FY2025.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-24) https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/gild-20251231.htm: "Cencora, Inc. 21%."

### 일라이 릴리 (high)  → /lilly-eli.md
- note: Cencora, formerly AmerisourceBergen, is one of the three major U.S. wholesalers to which Lilly sells rather than selling to pharmacies. Lilly's 10-K discloses that McKesson, Cencora, and Cardinal each account for 10%+ of consolidated revenue, making this distribution concentration a source of Cencora's channel bargaining power and the layer where the gross-to-net gap from rebates and PBMs forms.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-12) https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm: "Three U.S. wholesalers (McKesson, Cencora, Cardinal) each 10%+ of consolidated revenue"

### 존슨앤드존슨 (mid)  → /johnson-johnson.md
- note: Cencora is an authorized U.S. wholesale and specialty distributor for J&J Innovative Medicine, but no amount or share is attributed specifically to Cencora because J&J reports wholesaler concentration anonymously.
- [confirms] Janssen Pharmaceuticals, Inc. (EN, ir, published 2024-09-26) https://www.jnj.com/innovativemedicine/us/authorized-distributors-policies: "AMERISOURCEBERGEN DRUG CORPORATION (CENCORA). Wholesale/Distributor."

### 조에티스 (mid)  → /zoetis.md
- note: Cencora distributes Zoetis products into the U.S. veterinary market through its MWI Animal Health subsidiary, but because Zoetis disclosed in its 10-K that its largest U.S. veterinary distributor represented 16% of FY2025 revenue without naming the customer, the 16% is not attributed to Cencora here.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-12) https://www.sec.gov/Archives/edgar/data/1555280/000155528026000011/zts-20251231.htm: "Sales to our largest customer, a U.S. veterinary distributor, represented approximately 16% of total revenue for 2025."
- [mentions] ChoiceStock US (KO, analysis, published 2025-09-17) https://www.choicestock.co.kr/stock/research_view/6571: "The analysis says companion-animal products generate 68% of Zoetis revenue and the United States is its largest market, supporting the importance of the U.S. veterinary distribution channel."
- [confirms] SEC EDGAR (EN, filing, published 2015-01-12) https://www.sec.gov/Archives/edgar/data/1323974/000110465915001992/a15-2249_3ex99d1.htm: "If you look at some of our largest vendors, the biggest would be Zoetis."
- [confirms] SEC EDGAR (EN, filing, published 2013-11-27) https://www.sec.gov/Archives/edgar/data/1323974/000132397413000039/mwiv-20130930x10k.htm: "In 2013, Pfizer completed the spin off its animal health business as Zoetis, which is now our largest vendor, measured by revenues."

Reverse side: https://valuechain.wiki/cencora/customers.md · Ripple: https://valuechain.wiki/cencora/ripple.md

---
Full node: https://valuechain.wiki/cencora.md · JSON: https://valuechain.wiki/cencora.json